Envision Healthcare - Ein Medizindienstleister

zur AMR #75 ist direkt von der Envision home page.

www.evhc.net/vision/amr

Cantor Fitzgerald reissued their buy rating on shares of Envision Healthcare Holdings Inc (NASDAQ:EVHC) in a research report released on Monday morning, MarketBeat.Com reports. The brokerage currently has a $37.00 target price on the stock.

Mal sehen ob es jetzt zum Ausbruch kommt ...

www.stoxline.com/quote.php?symbol=evhc


www.bibeypost.com/...nvision-healthcare-holdings-inc-nyseevhc/

Envision Healthcare Holdings Inc. is in talks to merge with AmSurg Corp., a deal that would bring together two big providers of physician and other health-care services with a combined value of more than $9 billion.

Google ÜS :
https://translate.google.de/...s-merger%2F&edit-text=&act=url

www.bibeypost.com/...nvision-healthcare-holdings-inc-nyseevhc/

Envision Healthcare Holdings, Inc. (NYSE:EVHC) has been recommended as a long term growth pick according to Beta Research.  With their stock price currently trading around $27.35, the firm has proven a solid track record of growth over the past few years.  Investors might consider the stock as a long term growth candidate as the firm has yielded 19.00% earnings per share growth over the past 5 years and 13.80% revenue growth over that same time frame.  

Long-term growth (LTG) is an investing strategy where a stock will (hopefully) grow in value for a relatively long period of time.  Long-term growth should be considered to be a relative term, due to different styles and goals of investors, but the endgame is the same.

A “buy-and-hold” investor will consider long-term growth as a longer time period then a day trader will. The buy-and-hold strategy looks ahead farther into the future, giving short-term price swings less consideration as long as the fundamentals stay the same.  A trader is looking more closely at a weekly, or shorter, time frame and is more interested in immediate price fluctuations.

..ist der neue Name. Die Envison Aktionäre erhalten 53 % ,die Amsurg Akitonäre 47 % . Der Ticker ist weiterhin " EVHC" . Die Company ist an der NYSE gelistet. Chris Holden der CEO von Amsurg ist der neue CEO und William A. Sanger der CEO von Envision ist Executive Chairman of the Board.

http://www.bizjournals.com/nashville/news/2016/06/...unce-merger.html

Compelling Strategic and Financial Rationale

Compelling client proposition with differentiated service offerings: The combined organization will have complementary strengths as a physician-led, patient-focused healthcare services organization with a broad national footprint. The Company’s platform of differentiated service offerings will span from pre-hospital, acute and outpatient care to post-acute care.
   
Well positioned for evolving healthcare environment: As a leader in each of its sub-specialties, the combined organization will be able to use its expansive network to improve patient outcomes and experiences while creating efficiencies through more effective care coordination.

Strong financial profile: The combined company will have a strong balance sheet with anticipated Net Debt to Adjusted EBITDA at closing of 4.2x, including estimated contributions from recent acquisitions and estimated synergies. The Company will have a diversified business mix across verticals, geographies and clients, as well as significant cash-flow generation expected to be deployed for acquisitions, further driving growth while also reducing net leverage.

Meaningful synergy opportunities: The combination is expected to result in $100 million of synergies, anticipated to be fully realized within three years of closing. Synergies are expected to be derived through cost savings as well as meaningful revenue synergies from an enhanced portfolio and cross-selling opportunities.

Experienced, accomplished management team: The management team has a proven track record of building organizations for the changing healthcare environment and growth through both acquisitions and sales.

Significant accretion: The transaction is expected to be accretive to the two companies’ combined adjusted earnings per share in 2017 and double-digit accretive in 2018.

siehe auch :
http://www.bizjournals.com/nashville/news/2016/06/...unce-merger.html

Envision Healthcare Holdings Inc. agreed to buy AmSurg Corp., combining two large providers of physicians and other health-care services in an all-stock deal with an enterprise value of about $15 billion.

Aufschlag von letzter Woche sind dann wohl wieder weg .

27.51 -0.03 (-0.11%)
After Hours: 25.60 -1.91 (-6.94%)
Jun 15, 5:35PM EDT  

hat man mit mehr Prozentanteilen an der neuen Company gerechnet....

AmSurg

Der Gesundheitssektor bietet jede Menge Wachstumsaktien, aber da wir nur eine aussuchen können, schlage ich AmSurg  (WKN:911129) vor, einen Dienstleister im Bereich ambulante Chirurgie und Ärztedienste wie Anästhesiologie, Radiologie und Notfallmedizin.
BILDQUELLE: BIGSTOCK.

BILDQUELLE: BIGSTOCK.

Wie bei den meisten anderen Dienstleistern im Gesundheitssektor besteht meine größte Sorge darin, was mit Regierungsprogrammen wie Medicare und Medicaid passieren wird. Die Regierung hat klargestellt, dass man bei diesen Programmen weniger von den Unternehmen abhängig sein will, was Dienstleister wie AmSurg betreffen könnte.

Aber zumindest gibt es gute langfristige Wachstumsmöglichkeiten für AmSurg. Trotz der Sorgen um die Umsetzung von Obamacare sorgen weniger Unversicherte zu höheren Nutzungsraten. Das treibt die Nachfrage und die Preissetzungsmacht für die Dienste von AmSurg an. Im Steuerjahr 2015 sprangen die Umsätze pro Behandlungszentrum um 6 % im Bereich Ambulanz und um knapp 10 % im Bereich Ärztedienste.

Aber auch Übernahmen sind ein Thema für die Wachstumsaktien von heute. AmSurg hat im Sommer 2014 Sheridan Healthcare übernommen und ist seither nicht mehr zur Ruhe gekommen. Das Unternehmen hat 2015 ganze 16 Transaktionen getätigt und damit den Aktionären einen Umsatzanstieg von 58 % auf 2,57 Milliarden US-Dollar eingebracht. Das entspricht einem bereinigten Nettogewinnsprung um 68 % auf 191,3 Millionen US-Dollar.

Da die Lebenserwartung steigt und der Zugang zu medizinischer Versorgung immer besser wird, wird sich das Geschäft von AmSurg auch weiter erhöhen. Mit einem erwarteten KGV von 14 und einem KGWV von unter 0,9 könnte AmSurg genau das richtige sein.

Amsurg übertrifft im ersten Quartal mit einem Gewinn je Aktie von $0,82 die Analystenschätzungen von $0,78. Umsatz mit $724,7 Mio. über den Erwartungen von $705,27 Mio.

AmSurg übertrifft im vierten Quartal mit einem Gewinn je Aktie von $1,07 die Analystenschätzungen von $1,03. Umsatz mit $704,3 Mio über den Erwartungen von $681,71 Mio. / Quelle: Guidants News news.guidants.com

AmSurg erzielt im dritten Quartal mit einem Gewinn je Aktie von $1,03 (wie vorangekündigt). Umsatz mit $650,2 Mio über den Erwartungen von $632 Mio. / Quelle: Guidants News news.guidants.com

AmSurg übertrifft im abgelaufenen Geschäftsquartal mit einem Gewinn von $1,03 je Aktie die Analystenschätzungen von $0,95. Umsatz mit $650 Mio über den Erwartungen von $630 Mio / Quelle: Guidants News news.guidants.com

das heist soviel erreicht die Amsurg Aktie z.B 90 $ (aktuell 77,50 $) wird die Envision Aktie mit 30$ beim Umtausch gewichtet (Aktuell also in etwa 25,80 $ ).

ob der Deal rechtens ist..

Bala Cynwyd, 16. Juni 2016 (PR Newswire ) - Rechtsanwaltsbüro von Brodsky & Smith, LLC gibt bekannt, dass es künftige Ansprüche gegenüber dem Verwaltungsrat von Envision Healthcare Holdings, Inc. ( "Envision" oder "die Gesellschaft") wird untersucht ( NYSE- EVHC-News) wegen einer möglichen Verletzung der Treuepflicht und andere Verletzungen des staatlichen Rechts im Zusammenhang mit dem Verkauf des Unternehmens an AmSurg Corp. ( "AmSurg").

Anscheinend ist die Fusion nicht bestens für die Envision Aktionäre abgelaufen .Stand noch letztes Jahr der Aktienkurs deutlich höher. Deswgen wohl auch die untersuchungen

Acquisition May Not Be in the Best Interests of EVHC Shareholders .

Valinor Management LLC Increased Envision Healthcare Hldgs In (NYSE:EVHC) by $27.40 Million as Shares Declined

presstelegraph.com/2016/07/09/...0-million-as-shares-declined/

Bloom Tree Partners LLC Increased Envision Healthcare Hldgs In (NYSE:EVHC) by $32.35 Million as Shares Declined

www.engelwooddaily.com/...million-as-shares-declined-2/432317/

Alok Agrawal increased its stake in Envision Healthcare Hldgs In (NYSE:EVHC) by 62.86% based on its latest 2016Q1 regulatory filing with the SEC. Bloom Tree Partners Llc bought 1.62 million shares as the company’s stock declined 20.99% while stock markets rallied. The hedge fund run by Alok Agrawal held 4.19M shares of the health care company at the end of 2016Q1, valued at $85.49 million, up from 2.57 million at the end of the previous reported quarter. Bloom Tree Partners Llc who had been investing in Envision Healthcare Hldgs In for a number of months, seems to be bullish on the $4.83B market cap company. The stock decreased 0.20% or $0.05 during the last trading session, hitting $25.04. Envision Healthcare Holdings Inc (NYSE:EVHC) has declined 10.25% since December 1, 2015 and is downtrending. It has underperformed by 10.03% the S&P500.

-Earnings (Q2): $63.15 Mln. vs. $49.88 Mln. last year.
-Earnings Growth (Y-o-Y): 26.6%
-EPS (Q2): $1.10 vs. $0.97 last year.
-EPS Growth (Y-o-Y): 13.4%
-Analysts Estimate: $1.08
-Revenue (Q2): $859.83 Mln vs. $707.73 Mln last year.
-Revenue Change (Y-o-Y): 21.5%

GREENWOOD VILLAGE, Colo.--(BUSINESS WIRE)--Envision Healthcare Holdings, Inc. (Envision or Company) (NYSE: EVHC) reported results from operations for the three months and six months ended June 30, 2016. All comparisons included in this release are for the 2016 periods to the comparable 2015 periods, unless otherwise noted.

Highlights:

   Net revenue of $1.64 billion, an increase of 21.2%;
   Net income of $28.4 million compares with $52.4 million;
   Adjusted EBITDA of $172.0 million compares with $162.8 million;
   GAAP diluted earnings per share (EPS) was $0.15 and compares with $0.27; and
   Adjusted diluted EPS was $0.34 and compares with $0.37.

“Our results for the second quarter of 2016 reflect solid operating performance for our EmCare hospital-based physician services and legacy AMR operations,” said William A. Sanger, chairman, president and chief executive officer. “Our AMR financial results were impacted by investments made in certain Rural/Metro markets to meet customer service expectations and establish our position as valued partners in these communities. In addition, we experienced a delay in the expected earnings contribution from Evolution Health’s recently launched Florida health plan contract. We remain confident that we will achieve our targeted financial performance for both Rural/Metro and Evolution’s health plan contract during the first half of 2017. Our 2016 outlook is being updated to reflect the timing of expected improvements.”  

Envision erwartet, dass die vorläufige gemeinsame Proxy Statement / der Prospekt im Zusammenhang mit bereits angekündigten Fusion mit AMSURG Corp. (NASDAQ: AMSG) wird bei der US Securities and Exchange Commission am Donnerstag, den 4. August 2016 eingereicht werden, durch den neuen Registranten "New Amethyst Corp. ", die Envision Healthcare Corporation nach Abschluss der Fusion umbenannt wird.

Mal eben um 1.62 Mio Aktien aufgestockt.
 
Alok Agrawal increased its stake in Envision Healthcare Hldgs In (NYSE:EVHC) by 62.86% based on its latest 2016Q1 regulatory filing with the SEC. Bloom Tree Partners Llc bought 1.62 million shares as the company’s stock declined 20.99% while stock markets rallied. The hedge fund run by Alok Agrawal held 4.19 million shares of the health care company at the end of 2016Q1, valued at $85.49M, up from 2.57 million at the end of the previous reported quarter. Bloom Tree Partners Llc who had been investing in Envision Healthcare Hldgs In for a number of months, seems to be bullish on the $3.97 billion market cap company. The stock is up 5.19% or $1.07 after the positive news, hitting $21.7 per share. About 3.51M shares traded hands or 45.04% up from the average. Envision Healthcare Holdings Inc (NYSE:EVHC) has declined 4.93% since January 13, 2016 and is downtrending. It has underperformed by 20.38% the S&P500.

presstelegraph.com/2016/08/18/...5-million-as-shares-declined/

Bei Amsurg hat gestern auch jemand zugepackt zwei Blöcke a 300 K

Alok Agrawal's Bloom Tree Partners is one of the leading global long/short equity funds. The fund manages a 13F portfolio of $668 million as of the end of 2014. The fund's primary strategy is determining undervalued companies for its long portfolio and overvalued companies for its short portfolio by using extensive fundamental research. As of the end of last year, Bloom Tree's favorite picks were Google Inc GOOG, -0.31% FleetCor Technologies, Inc. FLT, +0.20% Comcast Corporation CMCSA, -0.53% Cheniere Energy, Inc. LNG, +1.67% and Twitter Inc TWTR, -0.16%